WASHINGTON (dpa-AFX) - ArQule, Inc. (ARQL) Thursday said it plans to present
the preliminary data from the ongoing phase 2 portion of a phase 1/2 trial in
intrahepatic cholangiocarcinoma with proprietary fibroblast growth factor
WASHINGTON (dpa-AFX) - ArQule, Inc. (ARQL) Thursday said its preliminary
clinical data for ARQ 087 demonstrated anti-cancer activity in Intrahepatic
Cholangiocarcinoma, a rare liver cancer with a high mortality rate and limited
WASHINGTON (dpa-AFX) - ArQule, Inc. (ARQL) said the company expects fiscal
2016 net loss to range between $24 and $27 million, and net loss per share to
range between $0.34 and $0.39. The company expects revenues to range between $4
TOKYO (dpa-AFX) - ArQule Inc. (ARQL) and Daiichi Sankyo announced that the
independent data monitoring committee or DMC of the METIV-HCC study conducted
the planned interim assessment and it was determined the trial will continue to
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.